

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

## MANUSCRIPT

### High burden of anti-microbial resistance among neonatal blood stream infections in Southeast Asia: results of the NeoSEAP study

Benjamin F R Dickson<sup>1</sup>, Nina Dwi Putri<sup>2</sup>, Riyadi Adrizain<sup>3</sup>, Leny Kartina<sup>4</sup>, Maria Esterlita Villaneuva Uy<sup>5</sup>, Gayana Gunaratna<sup>6</sup>, Chau Le<sup>7</sup>, Hoang Tran<sup>7</sup>, Huong Nguyễn Xuân<sup>8</sup>, Distayay Sukarja<sup>2</sup>, Tetty Yuniati<sup>3</sup>, Martono Utomo<sup>4</sup>, Nguyen Thi Kieu Trinh<sup>8</sup>, Hoang Nguyen Thanh Thuy<sup>9</sup>, Tran Thi Cam Tu<sup>10</sup>, Le Tuyet Hong<sup>11</sup>, Siew Moy Fong<sup>12</sup>, Michelle Harrison<sup>1</sup>, Phoebe C M Williams\*<sup>1</sup>, on behalf of the NeoSEAP consortium

<sup>1</sup>Faculty of Medicine & Health The University of Sydney, AUSTRALIA

<sup>2</sup>Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta INDONESIA

<sup>3</sup>Hasan Sadikin Hospital, University of Padjaran, Bandung, INDONESIA

<sup>4</sup>Soetomo Hospital, University of Airlangga, Surabaya INDONESIA

<sup>5</sup>Institute of Child Health and Human Development, National Institute of Health, Philippine General Hospital, Manila PHILIPPINES

<sup>6</sup>Colombo South Teaching Hospital, Colombo, SRI LANKA

<sup>7</sup>Da Nang Hospital for Women and Children, Da Nang, VIETNAM

<sup>8</sup>Pham Chau Trinh University, Da Nang, VIETNAM

<sup>9</sup>Da Nang Tam Tri General Hospital, Da Nang, VIETNAM

<sup>10</sup>Nha Trang Tam Tri General Hospital, Nha Trang, VIETNAM

<sup>11</sup>Dong Thap Tam Tri General Hospital, Dong Thap, VIETNAM

<sup>12</sup>Sabah Women's and Children's Hospital, Sabah, MALAYSIA

\*Corresponding author: [Phoebe.williams@sydney.edu.au](mailto:Phoebe.williams@sydney.edu.au)

## Abstract

**Background:** Progress on neonatal sepsis has remained modest in recent decades and is threatened by the global rise of antimicrobial resistance. The Southeast Asian region has a high burden of both neonatal sepsis and antimicrobial resistance. Despite this, there remains a lack of robust epidemiological data on the causes of neonatal sepsis and the prevalence of AMR in the region.

**Methods:** We evaluated the causes of neonatal sepsis and AMR burden in 10 sites across five countries in South and Southeast Asia (Sri Lanka, Indonesia, The Philippines, Malaysia and Vietnam). Retrospective data on all blood cultures collected from neonates between 1<sup>st</sup> January 2019 – 31<sup>st</sup> December 2020 were extracted from laboratory records. Data were also collected on the availability of clinical resources, the implementation of infection prevention and control strategies, and antimicrobial prescribing practices.

**Findings:** A total of 1,528 blood cultures were positive for significant isolates over the study period. Gram-negative pathogens predominated (1,163/1,528, 76.1%) with the most frequently isolated pathogens *Klebsiella* spp. (408/1,528, 26.7%) and *Acinetobacter* spp. (261/1,528, 17.08%). Among Gram-negative Enterobacteriaceae pooled resistance to ampicillin, gentamicin, third-generation cephalosporins (ceftriaxone and/or cefotaxime) and carbapenems was 75% (193/257), 59% (393/665), 67% (441/655) and 18.6% (125/672). For Gram negative non-Enterobacteriaceae resistance to gentamicin and carbapenems was 76.6% (326/282) and 69.7% (207/297).

**Interpretation:** Neonatal sepsis among study sites was caused predominantly by Gram-negative pathogens and associated with high levels of non-susceptibility to common empirical treatment regimes.

## Keywords

Neonatal sepsis, Neonatal meningitis, antimicrobial resistance, antibiotic resistance, Southeast Asia, Sri Lanka, Indonesia, The Philippines, Vietnam, Malaysia, Global health, child health.

## Introduction

Significant progress has been made in reducing child mortality in recent decades[1]. Despite this, neonatal deaths have only witnessed relatively modest improvements[1,2]. Sepsis remains an important cause of neonatal mortality with an estimated half a million deaths occurring annually[2]. Many survivors also face long-term sequelae including higher post-discharge mortality rates, cognitive and physical disabilities[3]. This burden disproportionately affects low- and middle-income countries (LMICs), where 85% of neonatal sepsis-related deaths occur[4].

Concurrently, the rise of antimicrobial resistance (AMR) threatens to halt, or even reverse recent global health gains[5]. Deaths from AMR are projected to outpace those from diabetes and cancer combined by 2050[5]. The AMR burden already does, and will continue to, inequitably fall on LMICs, where fragile health systems are less able to front this emerging challenge[5].

Neonates are particularly vulnerable to the rise of AMR. The rapid progression and non-specific presentation of neonatal sepsis drives high-rates of antimicrobial use. Simultaneously, premature infants experience long hospital admissions, which increase the probability of AMR colonisation and nosocomial infections. This risk is compounded in LMICs, where sepsis is predominantly caused by gram-negative infections, and overburdened health systems foster horizontal AMR transmission[6]. Emerging data in Africa and South Asia have demonstrated concerning levels of resistance to common first-, second- and third-line empirical treatment regimes to the extent that it is now estimated that one-third of neonatal sepsis deaths are directly attributable to AMR [7-11].

The Asian region has the highest global population, accounts for 40% of global cases of neonatal sepsis, and is anticipated to have the greatest number of deaths attributable to AMR by 2050[5,12,13]. Despite this, there remains a paucity of data on both the causes neonatal sepsis and the burden of AMR in this region [14]. These data are particularly critical in neonatal sepsis, where rates of culture-negative sepsis are high, so treatment relies heavily on empirical regimes based on known pathogen distributions, and susceptibility profiles[15].

This study therefore sought to contribute to this epidemiological gap by evaluating the causes of neonatal sepsis, and the associated burden of antimicrobial resistance across several countries in South and Southeast

105 Asia. To provide context to these data, it also assessed available healthcare resources, the implementation of  
106 infection prevention and control (IPC) strategies, and antimicrobial prescribing practices at each site.

## 108 **Methods**

### 109 *Study design*

110 This project was conducted by the Neonatal Sepsis in Southeast Asia and the Pacific (NeoSEAP) consortium.  
111 It was a multicentre, observational study conducted in 10 sites across five countries in South and Southeast  
112 Asia (Sri Lanka, Indonesia, The Philippines, Vietnam and Malaysia). The study included three components:  
113 1) a survey of available healthcare resources and utilisation of IPC strategies; 2) a retrospective audit of blood  
114 cultures collected from neonates over a 24-month period, and 3) a prospective antimicrobial point prevalence  
115 survey (PPS) evaluating the treatment, demographic and clinical data of all infants less than 180 days old.

### 116 *Site selection*

117 The study included countries with identified gaps in epidemiological data on the causative pathogens of  
118 neonatal sepsis and their associated AMR burden. Sites within each country were then selected through active  
119 recruitment.  
120

### 121 *Data collection*

122 Data were collected using the electronic data-collection instrument REDCap ([www.redcap.org](http://www.redcap.org)). Information  
123 on the availability of hospital resources and the implementation of IPC strategies was obtained from hospital  
124 records and staff, and then verified by site-visits where possible. During the PPS, all admitted infants receiving  
125 antimicrobial therapy at 8am on a pre-defined date between December 2022 and January 2023 were identified.  
126 Demographic, clinical and treatment data were then extracted from hospital records by clinical staff.  
127

128 Microbiological data from all blood cultures collected from neonates (defined as  $\leq 28$  days corrected  
129 gestational age) from 1<sup>st</sup> January 2019 to 31<sup>st</sup> December 2020 were systemically extracted from electronic  
130 and/or paper laboratory records. Data on the result, species (from a pre-defined list) and antimicrobial  
131 susceptibility profile were recorded. Positive cultures from the same patient with the same organism within  
132 four weeks were considered a repeat and were excluded from the study.  
133

134 The indication for neonatal blood culture collection in all sites was clinical instability and/or suspicion of a  
135 severe infection. Blood cultures were processed with the BacTec FX System (Becton Dickinson, Sparks USA)  
136 and/or BacT/ALERT 3D (bioMerieux, Inc. Durham USA) automated microbial detection systems. Positive  
137 cultures underwent identification and antimicrobial susceptibility testing using VITEK-2 (bioMerieux, Inc.  
138 Durham, USA), Phoenix (Becton Dickinson, Sparks USA) automated analysers, and conventional methods.  
139 In Sri Lanka, no automated analyser is available with pathogen identification for gram-negative pathogens  
140 limited to lactose-fermentation status, rather than genus or species level due to resource constraints.  
141 Antimicrobial susceptibility results were interpreted according to breakpoints established by Clinical and  
142 Laboratory Standards Institute (CLSI). Intermediate results were classified as resistant for the analysis.  
143

### 144 *Data analysis*

145 Data were managed in Microsoft Excel (Version 16) and analysed in Stata 16 (Stata corporation, TX).  
146 Proportions with exact 95% binomial confidence intervals were generated for pathogen frequency and AMR  
147 prevalence and compared using Chi-squared or Fisher exact tests. For the three Indonesian sites, country-level  
148 pooled coverage estimates for Ampicillin plus gentamicin, non-pseudomonal active third generation  
149 cephalosporins and carbapenems were generated using a weighted-incidence syndrome combination  
150 antibiogram (WISCA) as previously described[16]. No formal statistical evaluations of the association  
151 between AMR prevalence, resource availability and infection prevention and control strategies were  
152 undertaken because of the limited number of sites. The analysis of the PPS and fungal isolates will be reported  
153 separately.  
154

### 155 *Ethical approval*

156 Ethics approval was obtained from Universitas Indonesia, Jakarta; Institutional research board, Dr. Soetomo  
157 Hospital, Surabaya (0339/KEPK/XII/2021); and Komite Etik Penelitian RSUP Dr. Hasan Sadikin, Bandung.  
158  
159

Because the study was clinical audit, a waiver of participant consent was approved by the HREC committees at each site, and a waiver of ethical approval was granted for the Tam Tri Hospital Network.

## Results

### *Site characteristics and resources*

The characteristics and location of the 10 study sites included in the study are outlined in Table 1 and Figure 1. Seven of the sites were public tertiary teaching hospitals, whilst the remaining three were private referral hospitals (all located in Vietnam). All hospitals delivered infants on-site, with a median of 1,594.5 (IQR: 1,308 – 4,918) births per year. The median bed capacity (both post-natal ward and admitted) was 87 (IQR: 46 – 120) with an average of 1,168.5 (IQR: 247 – 1895) admissions per year. Among admitted infants the average proportion of premature infants was 41.9% (IQR: 11.3 – 51.8%). All ten sites had access to total-parenteral nutrition whilst nine (90%) were equipped with incubators, eight (80%) offered invasive ventilation and four (40%) had established donor milk programs.

### *Infection prevention & control strategies*

Figure 2. shows a heatmap of the infection prevention and control resources available and strategies implemented at each site. All ten sites had established local IPC guidelines, and the majority (90%) employed IPC specific staff. Antiseptic hand rub and gloves were always available at 6 (60%) and 9 (90%) of sites respectively. The median proportion of infants breastfeeding on discharge was 80% (IQR 70 – 92%). Kangaroo care was routine practiced by 9 (90%) sites.

### *Blood culture collection and empirical treatment regimes*

Table 2. outlines the blood culture collection practices and empirical treatment regimens by site. Seven of the 10 sites (70%) routinely collected blood-cultures prior to starting antibiotics, with 48 hours most frequently considered the cut-off for a negative culture (range: 48 hours – five days).

Most sites (90%) used multiple sources to inform empirical management practices of neonatal early- and late-onset sepsis and meningitis including national (100%), local (90%), World Health Organization (60%) and United Kingdom National Institute for Clinical Evidence (NICE) (20%) recommendations. Most local and national guidelines (89%) were published at least two or more years prior to the study. The predominant regime used for early-onset sepsis was ampicillin plus gentamicin (70%). In contrast, regimes for late-onset sepsis and meningitis were more varied, but most containing an aminoglycoside plus a penicillin-derivative and/or cephalosporin. Antibiotics classified in the ‘Watch’ group by the World Health Organization (WHO), were incorporated into empirical treatment regimens for late-onset sepsis, and meningitis in 60% and 80% sites respectively. Two sites (20%) recommended anti-fungal prophylaxis for at-risk infants: one using nystatin and the other fluconazole.

### *Neonatal blood cultures*

The number of neonatal blood cultures and the species isolated are shown in Table 3. Over the study period, there were a total of 1,528 positive blood cultures with clinically significant isolates as outlined alongside denominator data in Table 4. The median blood culture positivity rate from sites with available denominator data was 11.21 (IQR: 7.9 – 21.04%). Among significant isolates, gram-negatives predominated (1,163/1,528, 76.1%), followed by gram-positives (242/1,528, 15.8%) and *Candida* spp. 123/1,528 (8%).

The species identified in positive cultures are outlined in Figure 2. and Table 4. The most frequently isolated pathogens were *Klebsiella* spp. (408/1,528, 26.7%), *Acinetobacter* spp. (261/1,528, 17.08%) and *Enterobacter* spp. (98/1,528, 6.41%). The gram-positive species *S. aureus* and Group B Streptococcus only accounted for 3.34% (51/1,528) and 2.16% (33/1,528) of isolates respectively. There was a significant difference between the proportion of isolates caused by *Candida* spp. between sites with (12.2% 95%CI 9.0 – 15.9) and without anti-fungal prophylaxis (6.74%, 5.4 – 8.3%) (p=0.001).

Figure 3., Table 5., Table 6., and Table 7., outline the prevalence estimates of pooled and species-level AMR among positive bacterial isolates, while Figure 4., highlights the pooled non-susceptibility to key antimicrobials. Among gram-negative Enterobacteriaceae pooled resistance to ampicillin, gentamicin, third-generation cephalosporins (ceftriaxone and/or cefotaxime) (3GC) and carbapenems was 75% (193/257), 59%

(393/665), 67% (441/655) and 18.6% (125/672). Resistance to gentamicin and carbapenems was higher for gram-negative non-enterobacteriaeae at 76.6% (326/282) and 69.7% (207/297). Among gram-positives, the prevalence of methicillin-resistant *S. aureus* was 26.1% (12/46), and vancomycin-resistant *Enterococcus* spp. was 5.88% (4/68). Across all isolates, the prevalence of 3GC and carbapenem resistance was highest in Indonesia, Philippines and Sri Lanka, and lower in Malaysia and Vietnam. *Klebsiella* spp. and *Acinetobacter* spp., the two most prevalence species, harboured the highest prevalence of resistance to 3GCs (86%, 325/376) and carbapenems (77%, 194/252) respectively.

Of the 804 positive bacterial isolates from Indonesia, 710 (88%) had susceptibility data and were included in the Bayesian WISCA model. Estimated coverage was 25% (95% credible interval 22 to 29%) for aminopencillin plus gentamicin, 20% (17 to 23%) for 3GC, and 65% (62 to 69%) for carbapenems. More detailed results of these analyses have previously reported [16].

## Discussion

This study addressed important epidemiological gaps by evaluating the causes of neonatal sepsis, and the associated AMR burden in 10 sites across five countries in South and Southeast Asia. It demonstrated a predominance of gram-negative pathogens associated with alarming levels of resistance to commonly recommended empirical agents. These results highlight the urgent need for updated empirical treatment regimes, novel antimicrobial agents, and studies to understand the mechanisms of AMR development and spread in high-burden settings.

These findings align with observational studies elsewhere in Asia and Africa suggesting that gram-negative bacteria are the major cause of neonatal sepsis in resource-limited settings [6-10]. The predominance of *Klebsiella* spp. and *Acinetobacter* spp., which are typically associated with nosocomial infections, is consistent with findings elsewhere and underscores the likely role of horizontal transmission in the acquisition of AMR in these settings[8,15,17]. In contrast to high-income countries, the gram-positive bacteria Group B *Streptococcus* and *S. aureus*, appear to be less clinically important. Although not captured in this study, studies in similar settings with a high burden of *Klebsiella* spp. and *Acinetobacter* spp. indicate that the pathogen incidence between early- and late-onset infections were relatively similar[8,17].

The leading sepsis pathogens in this study all demonstrated concerning levels of resistance to major antimicrobial classes. These resistance rates were similar to those previously observed [8,9,17], highlighting the urgent need for novel antimicrobial agents to effectively treat the growing number of neonates in low- and middle-income countries with multi-drug resistant infections. The current WHO empirical treatment regimens do not provide sufficient coverage for the pathogen distribution and AMR burden in these settings[18]. In response, sites adapted their local regimes to improve likelihood of treatment success, but this was associated with high use of ‘watch’ classified antimicrobials and considerable variation in regimes used. Updated empirical treatment guidelines in settings with a high burden of multidrug resistant infections are therefore required to help inform healthcare providers and harmonise global practices. This guidance will require both greater data on the genetic mechanisms of resistance, as well as pathogen distribution and resistance patterns by early- and late-onset infections to ensure they provide sufficient and appropriate coverage.

Of note, the high burden of AMR observed in this study occurred in settings with well-established IPC programs. Most sites had deployed multiple strategies to mitigate AMR transmission but faced high clinical workloads compounded by limited staffing and resources. The variable gaps in each program, and the persistence of AMR despite these efforts demonstrates the need improved data on AMR transmission routes so that targeted interventions can be implemented to reduce the spread of AMR.

An important finding in this study was the high proportion of infections caused by *Candida* spp. (8%). Whilst anti-fungal prophylaxis was implemented in two-sites, the incidence of *Candida* spp. also remained considerable (6.7%) in sites not implementing prophylaxis. Given this burden of *Candida* spp. infections and demonstrated efficacy of anti-fungal prophylaxis in vulnerable infants, its widespread adoption in the region should be strongly considered [19].

269 These findings should be interpreted within the context of some study limitations. Firstly, sites were  
270 predominantly large, tertiary-care hospitals with complex-patient loads selected through non-random  
271 sampling. The observed pathogen distribution and resistance profiles may therefore not be generalisable to  
272 other health-care settings in the region. Secondly, blood culture data were retrospective and collected at the  
273 hospital level rather than the individual patient level. This method may have introduced bias and limited  
274 analyses of the timing and clinical correlates of infection. Lastly, the incomplete species-level identification  
275 in Sri Lanka hindered, and may have biased pooled species- and family-level estimates.

276  
277 This study nonetheless provides robust evidence that neonatal sepsis in these sites in South and Southeast Asia  
278 was caused predominantly by gram-negative pathogens with a high burden of AMR. It strengthens calls for  
279 updated empirical treatment regimes, and novel therapeutic agents to treat the increasing burden of multi-drug  
280 resistant infections. It also highlights the need for studies to better understand the acquisition and transmission  
281 AMR so that target interventions can developed.

### 282 **Contributions**

283 PCMW and BFRD designed the study. NDP, RA, LK, MEVU, GG, CL, HT, HNX and SMF collected study  
284 data. MS provided technical advice on the study design and interpretation. MH supported sites with data  
285 collection. BFRD and JB undertook the data analysis. BFRD and PCMW produced the first draft of the paper.  
286 All authors reviewed and approved the final draft of the paper.

### 287 **Acknowledgements**

288 We would like to thank the Dr. Le Xuan Tuy from Tam Tri General Hospitals  
289 ([tuy.le.dn@tmmchealthcare.com](mailto:tuy.le.dn@tmmchealthcare.com)); Dr. Helen Malinda Kurniawan ([helenmalindaa@gmail.com](mailto:helenmalindaa@gmail.com)) and Dr. Anisa  
290 Bela Anggraini Kolopaking ([anisakolopaking@gmail.com](mailto:anisakolopaking@gmail.com)) from Cipto Mangunkusumo Hospital); Dr Naritha  
291 Vermasari ([narithav@gmail.com](mailto:narithav@gmail.com)) and Dr Firstya Dyah ([firstyadiyah@gmail.com](mailto:firstyadiyah@gmail.com)) from Dr Soetomo  
292 Hospital); Dr Djatnika Setiabudi, Dr Anggraini alam, Dr Adhi Kristianto Sugianli and Dr Filla Reviyani  
293 Suryaningrat from (Hasan Sadikin Hospital); for their contribution to this project.

294  
295  
296  
297  
298 **Funding:** This study was supported by an Australian National Health and Medical Research Council  
299 (NHMRC) grant.

300  
301 **Declaration of Interest:** We declare no conflicts of interest.

### 302 **References**

- 303 1. Wang, H.; Abbas, K.M.; Abbasifard, M.; Abbasi-Kangevari, M.; Abbastabar, H.; Abd-Allah, F.;  
304 Abdelalim, A.; Abolhassani, H.; Abreu, L.G.; Abrigo, M.R. Global age-sex-specific fertility, mortality,  
305 healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019:  
306 a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *The Lancet* **2020**,  
307 *396*, 1160-1203.
- 308 2. Fleischmann, C.; Reichert, F.; Cassini, A.; Horner, R.; Harder, T.; Markwart, R.; Tröndle, M.; Savova, Y.;  
309 Kisson, N.; Schlattmann, P. Global incidence and mortality of neonatal sepsis: a systematic review  
310 and meta-analysis. *Archives of Disease in Childhood* **2021**, *106*, 745-752.
- 311 3. Organization, W.H. Global report on epidemiology and burden of sepsis: current evidence, identifying  
312 gaps and future directions [Internet]. Geneva, 2020.
- 313 4. Rudd, K.E.; Johnson, S.C.; Agesa, K.M.; Shackelford, K.A.; Tsoi, D.; Kievlan, D.R.; Colombara, D.V.; Ikuta,  
314 K.S.; Kisson, N.; Finfer, S. Global, regional, and national sepsis incidence and mortality, 1990–2017:  
315 analysis for the Global Burden of Disease Study. *The Lancet* **2020**, *395*, 200-211.
- 316 5. O'Neill, J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. *Rev.*  
317 *Antimicrob. Resist.* **2014**.
- 318 6. Chaurasia, S.; Sivanandan, S.; Agarwal, R.; Ellis, S.; Sharland, M.; Sankar, M.J. Neonatal sepsis in South  
319 Asia: huge burden and spiralling antimicrobial resistance. *bmj* **2019**, *364*.
- 320 7. Laxminarayan, R.; Matsoso, P.; Pant, S.; Brower, C.; Røttingen, J.-A.; Klugman, K.; Davies, S. Access to  
321 effective antimicrobials: a worldwide challenge. *The Lancet* **2016**, *387*, 168-175.
- 322

- 323 8. Agarwal, R.; Sankar, J. Characterisation and antimicrobial resistance of sepsis pathogens in neonates  
324 born in tertiary care centres in Delhi, India: a cohort study. *The Lancet Global Health* **2016**, *4*, e752-  
325 e760.
- 326 9. Li, G.; Bielicki, J.A.; Ahmed, A.N.U.; Islam, M.S.; Berezin, E.N.; Gallacci, C.B.; Guinsburg, R.; da Silva  
327 Figueiredo, C.E.; Vieira, R.S.; Silva, A.R. Towards understanding global patterns of antimicrobial use  
328 and resistance in neonatal sepsis: insights from the NeoAMR network. *Archives of disease in childhood*  
329 **2020**, *105*, 26-31.
- 330 10. Thomson, K.M.; Dyer, C.; Liu, F.; Sands, K.; Portal, E.; Carvalho, M.J.; Barrell, M.; Boostrom, I.;  
331 Dunachie, S.; Farzana, R. Effects of antibiotic resistance, drug target attainment, bacterial  
332 pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis:  
333 an international microbiology and drug evaluation prospective substudy (BARNARDS). *The Lancet*  
334 *Infectious Diseases* **2021**, *21*, 1677-1688.
- 335 11. Williams, P.C.; Isaacs, D.; Berkley, J.A. Antimicrobial resistance among children in sub-Saharan Africa.  
336 *The Lancet Infectious Diseases* **2018**, *18*, e33-e44.
- 337 12. United Nations. World population prospects. *United Nations Population Division* **2022**.
- 338 13. Li, J.; Xiang, L.; Chen, X.; Li, S.; Sun, Q.; Cheng, X.; Hua, Z. Global, regional, and national burden of  
339 neonatal sepsis and other neonatal infections, 1990–2019: findings from the Global Burden of Disease  
340 Study 2019. *European Journal of Pediatrics* **2023**, *182*, 2335-2343.
- 341 14. Moore, N.; Ashley, E.A.; Dickson, B.; Douangnouvong, A.; Panyaviseth, P.; Turner, P.; Williams, P.C.M.  
342 A Systematic Review of Antimicrobial Resistance Among Children in Low-and Middle-Income  
343 Countries in the Western Pacific Region (WPRO). Available at SSRN 4430748.
- 344 15. Milton, R.; Gillespie, D.; Dyer, C.; Taiyari, K.; Carvalho, M.J.; Thomson, K.; Sands, K.; Portal, E.A.; Hood,  
345 K.; Ferreira, A. Neonatal sepsis and mortality in low-income and middle-income countries from a  
346 facility-based birth cohort: an international multisite prospective observational study. *The Lancet*  
347 *Global Health* **2022**, *10*, e661-e672.
- 348 16. Putri, N.D.; Dickson, B.; Baker, J.; Adrizain, R.; Kartina, L.; Sukarja, D.; Cathleen, F.; Husada, D.; Utomo,  
349 M.T.; Yuniati, T. Epidemiology of Neonatal Sepsis in Indonesia: High Burden of Multidrug-Resistant  
350 Infections Reveals Poor Coverage Provided by Currently-Recommended Neonatal Sepsis Treatment  
351 Regimens.
- 352 17. Russell, N.J.; Stöhr, W.; Plakkal, N.; Cook, A.; Berkley, J.A.; Adhisivam, B.; Agarwal, R.; Ahmed, N.U.;  
353 Balasegaram, M.; Ballot, D. Patterns of antibiotic use, pathogens, and prediction of mortality in  
354 hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort  
355 study (NeoOBS). *PLoS Medicine* **2023**, *20*, e1004179.
- 356 18. Dale, H. WHO Pocket Book of Hospital Care for Children--Guidelines for the Management of Common  
357 Illnesses with Limited Resources. *Nursing Standard* **2006**, *20*, 36-37.
- 358 19. Cleminson, J.; Austin, N.; McGuire, W. Prophylactic systemic antifungal agents to prevent mortality  
359 and morbidity in very low birth weight infants. *Cochrane Database of Systematic Reviews* **2015**.
- 360

**Tables, Figures and Supplemental Data**

62  
63  
64  
65




Figure 1. Map of included countries and study sites

66



**Table 1. Characteristics of NeoSEAP sites**

		Indonesia			Philippines	Sri Lanka	Malaysia	Vietnam				
Site		1	2	3	4	5	6	7	8	9	10	
Care type	Ownership	Public Tertiary	Public Tertiary	Public Tertiary	Public Tertiary	Public Tertiary	Public Tertiary	Public Tertiary	Private Referral	Private Referral	Private Referral	
Beds	Post-natal ward	2	24	28	48	30	104	107	25	40	40	
	Special-care Nursery	17	24	40	30	6	58	12			6	
	HDU	19	44	32	0	10	24	111	10^	54^	0	
	ICU	30	14	20	30	8	18	49			0	
	<b>Total</b>	68	106	120	108	54	204	279	25	40	46	
Staffing	Nurses (Total FTE)	116	64	53	42	25	162	61	3	0	12	
	Doctor (Total FTE)	14	7	8	24	12	25	14	1	0	4	
	Consultant (Total FTE)	1	3	4	7	2	1	3	1	0	1	
Deliveries	Deliveries on-site	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	Birth per year	1,508	1,681	853	3,365	4,918	14,052	10,159	492	1,308	1,339	
Admissions	Total	1,433	1,895	1,490	904	398	6,081	2,448	52	215	247	
	Premature	823	797	715	864	206	986	1,023	1	12	28	
Services	Neonatal Surgery	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	No	
	Incubators (number)	17	40	43	27	16	29	17	1	0	1	
	Non-invasive ventilation	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	
	Invasive ventilation	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	
	Inotropes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
	TPN	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	Donor-milk	Yes	No	No	Yes	No	No	Yes	No	No	Yes	

^Neonatal beds on paediatric ward

**Table 2. Empirical antimicrobial recommendations by site**

Country		Indonesia			Philippines	Sri Lanka	Malaysia	Vietnam			
Site		1	2	3	4	5	6	7	8	9	10
Blood cultures	Routine pre-treatment	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No
	Culture negative cut-off (time)	5 days	48 hours	72 hours	48 hours	48 hours	48 hours	72 hours	48 hours	5 days	48 hours
Treatment guidelines used (update year)		Local (2019), National (2019), WHO	Local (2020), National (2018), WHO	Local (2016), National (2016), WHO	Local (2016), National (2020)	Local (2016), National (2014), NICE	Local (2020), National (2018), WHO	Local (2021), National (2016), WHO	National (2022)	Local (2020), National (2015), Children's Hospital 1	Local (2020), National (2015), WHO, NICE
Empirical antimicrobial regimes*	EONS	AMP 50 mg/kg TDS GEN 5 mg/kg OD	AMP 100 mg/kg BD GEN 4 mg/kg OD	AMP 50 mg/kg BD GEN 5 mg/kg OD	AMP 50 mg/kg TDS AMK 15 mg/kg OD	PEN 100 mg/kg BD GEN 5 mg/kg OD	AMP 50 mg/kg BD GEN 5 mg/kg OD	AMP 50 mg/kg TDS GEN 4 mg/kg OD	AMP 150 mg/kg BD GEN 5 mg/kg OD	AMP 150 mg/kg TDS AMK 15 mg/kg OD	AMP 150 mg/kg TDS GEN 4 mg/kg OD
										CTX 100 mg/kg BD	
	LONS	AMP/Sulbac. 50 mg/kg TDS GEN 5 mg/kg OD	CTX 150 mg/kg TDS . .	AMP 50 mg/kg BD GEN 5 mg/kg OD	CAZ 100 mg/kg TDS AMK 15 mg/kg OD	PEN 100 mg/kg BD CTX 50 mg/kg TDS	Cloxacillin 50mg/kg BD GEN 5 mg/kg OD	Ticarcillin 80 mg/kg QID AMK 15 mg/kg OD	CTX 150 mg/kg TDS GEN 5 mg/kg OD	AMP 150 mg/kg TDS CTX 150 mg/kg TDS AMK 15 mg/kg OD	AMP 150 mg/kg BD GEN 4 mg/kg OD
	Meningitis	AMP/Sulbac. 50 mg/kg TDS GEN 5 mg/kg OD	MEM 40 mg/kg TDS	CTX 100 mg/kg BD GEN 8 mg/kg OD	AMP 50 microg/kg TDS AMK 15 mg/kg OD	CTX 50 mg/kg TDS	PEN 100,000 IU/kg BD CTX 50 mg/kg BD	AMP 50 mg/kg QID GEN 4mg/kg OD CTX 50mg/kg QID	CTX 100 mg/kg OD GEN 5mg/kg OD	AMP 300 mg/kg QID AMK 15 mg/kg OD CTX 200 mg/kg QID	AMP 300 mg/kg TDS GEN 4mg/kg OD CTX 300 mg/kg TDS
Anti-fungal prophylaxis	Recommended	No	No	Nystatin 100,000 IU PO TDS^	Fluconazole 3mg/kg IV q72h~	No	No	No	No	No	No

\*Colour refers AWaRe classification: Access (green), Watch (yellow), Reserve (red). All antibiotic doses are intravenous. OD (Once daily), BD (Twice daily), TDS (Three times daily), QID (Four times daily).

^Nystatin criteria: Weight <1500g; GA <32 weeks. ~Fluconazole criteria: Weight <= 1500g + broad spectrum Abx;

Weight >1500g + NBM >5 days. AMP (Ampicillin), GEN (Gentamicin), AMK (Amikacin), MEM (Meropenem), CAZ (Ceftazidime), CTX (Cefotaxime or Ceftriaxone)

**Table 3. Frequency of bacterial isolates in neonatal blood cultures by site (n=1,405)**

Country		Indonesia			Philippines	Sri Lanka	Vietnam	Total
Site	Pathogen	1	2	3	4	5	7	
Gram negative (n) (%)	<b>Acinetobacter spp.</b>	90 (20.22)	61 (18.94)	11 (12.09)	67 (24.01)	30 (30.61)	1 (0.44)	261 (17.08)
	<b>Citrobacter spp.</b>	2 (0.45)	0	0	0	0	0	2 (0.13)
	<b>E. coli</b>	19 (4.27)	31 (9.63)	7 (7.69)	14 (5.02)	1 (1.02)	9 (4)	96 (6.28)
	<b>Enterobacter spp.</b>	62 (13.93)	5 (1.55)	6 (6.59)	9 (3.23)	7 (7.14)	1 (0.44)	98 (6.41)
	<b>Klebsiella spp.</b>	204 (45.84)	64 (19.88)	33 (36.26)	92 (32.97)	2 (2.04)	6 (2.67)	408 (26.7)
	<b>Lactose-fermenting (LF) coliforms</b>	0	0	0	0	14 (14.29)	0	14 (0.92)
	<b>Non-lactose-fermenting (NLF) coliforms</b>	0	0	0	0	11 (11.22)	0	11 (0.72)
	<b>Non-typhoid Salmonella</b>	0	21 (6.52)	0	0	0	0	21 (1.37)
	<b>Proteus spp.</b>	1 (0.22)	2 (0.62)	0	0	0	0	4 (0.26)
	<b>Pseudomonas spp.</b>	17 (3.82)	6 (1.86)	4 (4.4)	8 (2.87)	5 (5.1)	1 (0.44)	46 (3.01)
	<b>S. typhi</b>	(0)	2 (0.62)	0	1 (0.36)	0	0	3 (0.2)
	<b>Serratia spp.</b>	3 (0.67)	9 (2.8)	6 (6.59)	40 (14.34)	1 (1.02)	9 (4)	69 (4.52)
	<b>Other</b>	8 (1.8)	17 (5.28)	1 (1.1)	0 (0)	5 (5.1)	94 (41.78)	130 (8.51)
	<b>Total</b>		406 (0)	218 (67.7)	68 (74.73)	231 (82.8)	76 (77.55)	121 (53.78)
Gram positive (n) (%)	<b>Enterococcus spp.</b>	9 (2.02)	7 (2.17)	0	7 (2.51)	6 (6.12)	0	30 (1.96)
	<b>Group A Streptococcus</b>	1 (0.22)	1 (0.31)	0	0	1 (1.02)	0	3 (0.2)
	<b>Group B Streptococcus</b>	1 (0.22)	11 (3.42)	0	2 (0.72)	12 (12.24)	2 (0.89)	33 (2.16)
	<b>S. aureus</b>	7 (1.57)	7 (2.17)	2 (2.2)	5 (1.79)	7 (7.14)	7 (3.11)	51 (3.34)
	<b>S. pneumoniae</b>	0	0	0	0	0	0	1 (0.07)
	<b>Other</b>	0 (0)	56 (17.39)	10 (10.99)	0 (0)	-10 (-10.2)	66 (29.33)	124 (8.12)
	<b>Total</b>		18 (4.04)	82 (25.47)	12 (13.19)	14 (5.02)	16 (16.33)	75 (33.33)

Country #		IN	PH	SL	ML	VN					
Site		1	2	3	4	5	6	7	8	9	10
Hospital IPC guidelines & staffing (Yes/No)	Local IPC guideline										
	IPC specific staff										
	IPC unit										
	IPC staff training										
	IPC audits										
	HAI reporting										
	HAI surveys										
Handwash availability (proportion of time)*	Room entry										
	Bedside										
PPE availability (proportion of time)*	Gloves (non-sterile)										
	Gloves (sterile)										
	Mask (surgical)										
	Mask (N95)										
	Sterile Gown										
	Sterile Drape										
	Antiseptic										
	Autoclave										
	Eye protection										
	Equipment cleaning (type)~	Medical									
Resuscitation											
Feeding											
Equipment change (frequency)^	IV set										
	Incubator water										
	NIV water										
	Ventilator water										
Breastfeeding (proportion)&	Discharge										
	At 6 weeks										
Lactation support available (Yes/No)											
Donor milk available (Yes/No)											
Kangaroo care available (Yes/No)											

\*Criteria: frequency of time: Green (100%), Yellow (50-100%), Red (<50%). ~Criteria: Green (Sterilisation), Yellow (Disinfection), Red (Soap & water). ^Criteria: Green (Daily), Yellow (2-3 times weekly), Red (Less than 2-3 weekly).& Criteria: Green (76-100%), Yellow (50-75%), Red (<50%)


**Figure 2. Heatmap of resource availability and Infection prevention & control strategies by site**

**Table 4. Blood culture denominators by site**

Country	IN			PH	SL	ML	VN				Total
Site	1	2	3	4	5	6	7	8	9	10	
<b>Blood cultures analysed</b>	2059	1649	1731	3831	-	2525	3004	0	0	5	14804
<b>Positive cultures</b>	<b>Including contaminants</b>										
	614	-	179	525	124	94	273	0	0	0	1809
<b>Significant isolates</b>	<b>Total</b>										
	445	322	91	279	98	68	225	0	0	0	<b>1528</b>
	<b>Total core^</b>										
	437	249	80	279	103	61	65	0	0	0	1274
	<b>Total core with AST</b>										
	407	208	76	278	99	61	45	0	0	0	1174
	<b>Gram-positive*</b>										
	18	82	12	14	16	25	75	0	0	0	242
	<b>Gram-negative</b>										
	406	218	68	231	76	43	121	0	0	0	1163
	<b>Candida spp.</b>										
	21	22	11	34	6	0	29	0	0	0	123

\*Excluding Coagulase-negative Staphylococci. ^Core organisms referred to pathogen species captured in the study, other pathogens were grouped as 'other'. \*AST (Antimicrobial susceptibility testing). #IN (Indonesia), PH (Philippines), SL (Sri Lanka), ML (Malaysia), VN (Vietnam).

**1528**



**Figure 3. Pooled frequency of positive bacterial isolates**

**Table 5. Pooled antimicrobial susceptibility of neonatal blood culture isolates by site and pathogen type**

Antimicrobial	Indonesia			Philippines	Sri Lanka	Malaysia	Vietnam	Total
	1	2	3	4	5	6	7	
	(n/N) (%)	(n/N) (%)	(n/N) (%)	(n/N) (%)	(n/N) (%)	(n/N) (%)	(n/N) (%)	(n/N) (%)
<b>Gram-negative non-Enterobacteriaceae</b>								
Amikacin	66/97 (68.04)	38/62 (61.29)	8/15 (53.33)	3/70 (4.29)	28/34 (82.35)	0/6 (0)	0/1 (0)	143/285 (50.18)
Carbapenems	73/102 (71.57)	49/62 (79.03)	7/15 (46.67)	49/75 (65.33)	28/35 (80)	0/6 (0)	1/2 (50)	207/297 (69.7)
Cefepime	42/58 (72.41)	60/62 (96.77)	12/15 (80)	54/75 (72)	0/0 (0)	0/5 (0)	1/2 (50)	169/217 (77.88)
Ceftazidime	57/79 (72.15)	58/62 (93.55)	12/15 (80)	53/75 (70.67)	30/32 (93.75)	0/6 (0)	0/2 (0)	210/271 (77.49)
Ciprofloxacin	61/86 (70.93)	54/62 (87.1)	0/15 (0)	48/75 (64)	22/27 (81.48)	0/6 (0)	1/2 (50)	186/273 (68.13)
Co-trimoxazole	9/29 (31.03)	18/57 (31.58)	0/11 (0)	16/67 (23.88)	24/26 (92.31)	0/0 (0)	0/0 (0)	67/190 (35.26)
Gentamicin	69/92 (75)	57/62 (91.94)	12/15 (80)	51/75 (68)	25/30 (83.33)	1/6 (16.67)	1/2 (50)	216/282 (76.6)
Piperacillin-Tazobactam	71/100 (71)	58/62 (93.55)	9/15 (60)	53/75 (70.67)	0/0 (0)	0/6 (0)	0/1 (0)	191/259 (73.75)
Tigecycline	19/95 (20)	11/62 (17.74)	3/15 (20)	0/0 (0)	0/0 (0)	0/0 (0)	0/0 (0)	33/172 (19.19)
Tobramycin	0/0 (0)	0/0 (0)	0/15 (0)	11/75 (14.67)	0/0 (0)	0/0 (0)	1/2 (50)	12/92 (13.04)
<b>Gram-negative Enterobacteriaceae</b>								
3GC	196/251 (78.09)	77/105 (73.33)	38/52 (73.08)	88/155 (56.77)	29/35 (82.86)	4/32 (12.5)	9/25 (36)	441/655 (67.33)
Amikacin	115/257 (44.75)	38/105 (36.19)	12/52 (23.08)	18/155 (11.61)	7/31 (22.58)	1/24 (4.17)	0/12 (0)	191/636 (30.03)
Aminopenicillin	52/77 (67.53)	50/52 (96.15)	0/13 (0)	43/63 (68.25)	24/27 (88.89)	24/25 (96)	0/0 (0)	193/257 (75.1)
Amoxicillin-Clavulanate	180/274 (65.69)	81/91 (89.01)	38/52 (73.08)	114/155 (73.55)	30/33 (90.91)	20/32 (62.5)	19/24 (79.17)	482/661 (72.92)
Carbapenems	60/274 (21.9)	13/105 (12.38)	9/52 (17.31)	23/155 (14.84)	20/33 (60.61)	0/28 (0)	0/25 (0)	125/672 (18.6)
Cefepime	113/165 (68.48)	41/91 (45.05)	44/52 (84.62)	84/155 (54.19)	0/0 (0)	3/32 (9.38)	7/25 (28)	292/520 (56.15)
Ceftazidime	160/212 (75.47)	80/91 (87.91)	40/52 (76.92)	83/155 (53.55)	20/25 (80)	3/32 (9.38)	7/25 (28)	393/592 (66.39)
Ciprofloxacin	134/236 (56.78)	55/105 (52.38)	0/52 (0)	40/155 (25.81)	19/31 (61.29)	8/32 (25)	4/25 (16)	260/636 (40.88)
Co-trimoxazole	72/125 (57.6)	49/105 (46.67)	0/52 (0)	51/155 (32.9)	13/24 (54.17)	12/32 (37.5)	6/13 (46.15)	203/506 (40.12)
Fosfomycin	0/0 (0)	0/0 (0)	8/52 (15.38)	0/0 (0)	0/0 (0)	0/0 (0)	0/0 (0)	8/52 (15.38)
Gentamicin	205/262 (78.24)	90/105 (85.71)	34/52 (65.38)	26/155 (16.77)	21/34 (61.76)	7/32 (21.88)	10/25 (40)	393/665 (59.1)
Netilmicin	0/0 (0)	0/0 (0)	2/52 (3.85)	0/40 (0)	8/15 (53.33)	0/0 (0)	0/0 (0)	10/107 (9.35)
Piperacillin-Tazobactam	16/61 (26.23)	3/12 (25)	3/12 (25)	0/49 (0)	0/1 (0)	1/10 (10)	0/1 (0)	23/146 (15.75)
Tigecycline	5/263 (1.9)	5/91 (5.49)	20/52 (38.46)	0/0 (0)	0/0 (0)	0/0 (0)	0/0 (0)	30/406 (7.39)
Tobramycin	0/0 (0)	0/0 (0)	0/52 (0)	2/141 (1.42)	0/0 (0)	0/0 (0)	7/25 (28)	9/218 (4.13)
Trimethoprim	0/0 (0)	43/91 (47.25)	0/52 (0)	0/0 (0)	0/0 (0)	0/0 (0)	5/12 (41.67)	48/155 (30.97)

Note: Antibiotics excluded with less than a pooled totals of 50 isolates (Gram-negative) and 20 isolates (Gram-positive)

**Table 6. Pooled antimicrobial susceptibility of neonatal blood culture isolates by site and pathogen type (continued)**

Gram Positive								
3GC	1/1 (100)	0/10 (0)	/ (0)	0/2 (0)	0/2 (0)	0/6 (0)	0/1 (0)	1/22 (4.55)
Aminopenicillin	3/13 (23.08)	0/6 (0)	0/2 (0)	4/7 (57.14)	0/6 (0)	0/1 (0)	0/0 (0)	7/35 (20)
Methicillin	0/2 (0)	0/4 (0)	0/2 (0)	2/5 (40)	3/7 (42.86)	1/16 (6.25)	6/7 (85.71)	12/43 (27.91)
Clindamycin	1/2 (50)	4/14 (28.57)	0/2 (0)	1/7 (14.29)	5/13 (38.46)	5/21 (23.81)	7/9 (77.78)	23/68 (33.82)
Co-trimoxazole	0/3 (0)	0/4 (0)	0/2 (0)	0/0 (0)	1/7 (14.29)	1/17 (5.88)	5/6 (83.33)	7/39 (17.95)
Erythromycin	0/2 (0)	3/10 (30)	/ (0)	0/2 (0)	3/8 (37.5)	2/5 (40)	2/2 (100)	10/29 (34.48)
Penicillin	5/9 (55.56)	0/20 (0)	1/2 (50)	7/14 (50)	2/21 (9.52)	15/22 (68.18)	6/9 (66.67)	36/97 (37.11)
Teicoplanin	0/13 (0)	0/0 (0)	0/2 (0)	0/0 (0)	0/0 (0)	0/0 (0)	0/7 (0)	0/22 (0)
Vancomycin	2/12 (16.67)	0/10 (0)	0/2 (0)	2/12 (16.67)	0/7 (0)	0/18 (0)	0/7 (0)	4/68 (5.88)


Note: Antibiotics excluded with less than a pooled totals of 50 isolates (Gram-negative) and 20 isolates (Gram-positive)



**Table 7. Pooled antimicrobial susceptibility of common species to select antimicrobials by site**

Antimicrobial	Indonesia			Philippines	Sri Lanka	Malaysia	Vietnam	Total
	1 (n/N) (%)	2 (n/N) (%)	3 (n/N) (%)	4 (n/N) (%)	5 (n/N) (%)	6 (n/N) (%)	7 (n/N) (%)	(n/N) (%)
<b>Aminopenicillin</b>								
E. coli	8/17 (47.06)	26/26 (100)	0/7 (0)	10/14 (71.43)	0/1 (0)	14/15 (93.33)	0	58/80 (72.5)
Enterobacter	42/55 (76.36)	5/5 (100)	0	2/9 (22.22)	4/4 (100)	8/8 (100)	0	61/81 (75.31)
Enterococcus	2/8 (25)	0/6 (0)	0	4/7 (57.14)	0/6 (0)	0/1 (0)	0	6/28 (21.43)
Serratia	1/2 (50)	6/6 (100)	0/6 (0)	31/40 (77.5)	1/1 (100)	1/1 (100)	0	40/56 (71.43)
<b>Gentamicin</b>								
Acinetobacter	66/77 (85.71)	55/57 (96.49)	10/11 (90.91)	48/67 (71.64)	23/25 (92)	1/1 (100)	0/1 (0)	203/239 (84.94)
E. coli	9/17 (52.94)	23/26 (88.46)	4/7 (57.14)	3/14 (21.43)	0/1 (0)	6/15 (40)	6/9 (66.67)	51/89 (57.3)
Enterobacter	33/55 (60)	0/5 (0)	3/6 (50)	3/9 (33.33)	6/7 (85.71)	0/8 (0)	0/1 (0)	45/91 (49.45)
Klebsiella	161/185 (87.03)	50/53 (94.34)	26/33 (78.79)	20/92 (21.74)	0/2 (0)	0/7 (0)	4/6 (66.67)	261/378 (69.05)
Pseudomonas	3/15 (20)	2/5 (40)	2/4 (50)	3/8 (37.5)	2/5 (40)	0/5 (0)	1/1 (100)	13/43 (30.23)
Serratia	2/2 (100)	3/6 (50)	1/6 (16.67)	0/40 (0)	1/1 (100)	1/1 (100)	0/9 (0)	8/65 (12.31)
<b>3rd Generation Cephalosporins</b>								
E. coli	9/19 (47.37)	3/26 (11.54)	4/7 (57.14)	4/14 (28.57)	0/1 (0)	2/15 (13.33)	5/9 (55.56)	27/91 (29.67)
Enterobacter	26/44 (59.09)	5/5 (100)	3/6 (50)	2/9 (22.22)	5/6 (83.33)	0/8 (0)	0/1 (0)	41/79 (51.9)
GBS~	1/1 (100)	0/9 (0)	0	0/2 (0)	0/2 (0)	0/5 (0)	0/1 (0)	1/20 (5)
Klebsiella	158/183 (86.34)	53/53 (100)	30/33 (90.91)	77/92 (83.7)	2/2 (100)	1/7 (14.29)	4/6 (66.67)	325/376 (86.44)
Serratia	2/2 (100)	3/6 (50)	1/6 (16.67)	5/40 (12.5)	1/1 (100)	1/1 (100)	0/9 (0)	13/65 (20)
<b>Carbapenems</b>								
Acinetobacter	68/85 (80)	47/57 (82.46)	6/11 (54.55)	46/67 (68.66)	27/30 (90)	0/1 (0)	0/1 (0)	194/252 (76.98)
E. coli	5/17 (29.41)	9/26 (34.62)	2/7 (28.57)	2/14 (14.29)	0/1 (0)	0/15 (0)	0/9 (0)	18/89 (20.22)
Enterobacter	8/56 (14.29)	0/5 (0)	1/6 (16.67)	0/9 (0)	6/7 (85.71)	0/4 (0)	0/1 (0)	15/88 (17.05)
Klebsiella	47/195 (24.1)	4/53 (7.55)	6/33 (18.18)	20/92 (21.74)	1/2 (50)	0/7 (0)	0/6 (0)	78/388 (20.1)
Pseudomonas	5/17 (29.41)	2/5 (40)	1/4 (25)	3/8 (37.5)	1/5 (20)	0/5 (0)	1/1 (100)	13/45 (28.89)
Serratia	0/3 (0)	0/6 (0)	0/6 (0)	1/40 (2.5)	0/1 (0)	0/1 (0)	0/9 (0)	1/66 (1.52)
<b>Penicillin</b>								
Enterococcus	2/7 (28.57)	0/6 (0)	0	4/7 (57.14)	0/6 (0)	0	0	6/26 (23.08)
GBS	0	0/9 (0)	0	0/2 (0)	0/12 (0)	0/5 (0)	0/2 (0)	0/30 (0)
S. aureus	2/1 (200)	0/4 (0)	1/2 (50)	3/5 (60)	2/2 (100)	15/16 (93.75)	6/7 (85.71)	29/37 (78.38)
<b>Methicillin</b>								
S. aureus	0/2 (0)	0/4 (0)	0/2 (0)	2/5 (40)	3/7 (42.86)	1/16 (6.25)	6/7 (85.71)	12/43 (27.91)
<b>Vancomycin</b>								
Enterococcus	2/6 (33.33)	0/6 (0)	0	2/7 (28.57)	0/0 (0)	0/1 (0)	0	4/20 (20)
S. aureus	0/6 (0)	0/4 (0)	0/2 (0)	0/5 (0)	0/7 (0)	0/16 (0)	0/7 (0)	0/47 (0)

Note: Species with less than 15 total isolates omitted from table. ~GBS (Group B Streptococcus)



**Figure 4. Pooled non-susceptibility to key antimicrobials for a) Gram-negative pathogens and b) Gram-positive pathogens**